Open Label, Safety and Efficacy Study of Topical Investigational Drug to Treat Patients With Psoriasis

ClinicalTrials.gov ID: NCT00617994

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00617994. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 7:31 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

An Open Label, Safety, Tolerability, Pharmacokinetic (PK), Pharmacodynamic (PD) and Preliminary Efficacy Study of Ruxolitinib When Applied to Patients With Plaque Psoriasis Involving 2 - 20% Body Surface Area (BSA).

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This will be an open label study of ruxolitinib topical cream applied to 2 - 20% BSA in patients with active, stable plaque psoriasis.

Study identification

NCT ID: NCT00617994
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Incyte Corporation; Industry
Enrollment: 25 participants

Conditions and interventions

Conditions

Psoriasis

Interventions

Ruxolitinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 31, 2007 (Actual)
Primary completion: Apr 30, 2009 (Actual)
Completion: May 31, 2009 (Actual)
Last update posted: Feb 8, 2022

2007 – 2009

United States locations

U.S. sites: 4
U.S. states: 3
U.S. cities: 4

Facility	City	State	ZIP	Site status
Not listed	Fridley	Minnesota	55432	—
Not listed	Rochester	New York	14623	—
Not listed	Austin	Texas	78759	—
Not listed	College Station	Texas	77840	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00617994, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 8, 2022 · Synced Nov 13, 2026